EC ap­proves Bio­Marin drug as first treat­ment for chil­dren with com­mon form of dwarfism; Servi­er sN­DA wins ap­proval

The Eu­ro­pean Com­mis­sion just ap­proved its first drug for use in chil­dren with achon­dropla­sia, a com­mon form of dwarfism.

Bio­Marin re­ceived mar­ket­ing au­tho­riza­tion

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER